<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528605</url>
  </required_header>
  <id_info>
    <org_study_id>NNSFC-30872113</org_study_id>
    <nct_id>NCT01528605</nct_id>
  </id_info>
  <brief_title>Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration</brief_title>
  <official_title>The Effects of Lutein and Zeaxanthin Supplementations on Early Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the protective effects of supplemental lutein and zeaxanthin on
      early age-related macular degeneration (AMD) patients in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early age-related macular degeneration (AMD) is an early hallmark of irreversible vision
      impairment accompanying with senescence of macular. Given the fact in treatment, prevention
      strategy is thought to be an efficient and robust approach to diminish early AMD patients in
      low-income countries, however, feasible cocktail provision in most developing nations remain
      mysteries. Here we proposed an effective cocktail treatment with different amounts of lutein
      and zeaxanthin could increase the macular pigment optical density (MPOD) and serum
      xanthophylls concentrations among randomized Chinese AMD patients; and might improve visual
      function measured by visual performance indices such as best-spectacle corrected visual
      acuity (BSCVA), contrast sensitivity (CSF), flash recovery time (FRT), multifocal
      electroretinogram (mfERG) and microperimetry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years</measure>
    <time_frame>at baseline and 24 weeks, 48 weeks, 2 years during the intervention</time_frame>
    <description>Macular pigment is found in the center of the retina known as the macula and is made up of the carotenoids lutein and zeaxanthin. This pigment serves to protect the macula from harmful blue light. The MPOD ranges from 0 to 1, with higher scores corresponding with greater density (protection). The autofluorescence picture of subject's macular was analyzed for MPOD values.
4 participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Serum Xanthophylls Concentrations During the Intervention</measure>
    <time_frame>at baseline and 4, 12, 24 and 48 weeks during the intervention</time_frame>
    <description>Changes of serum xanthophylls concentrations measured by high performance liquid chromatograph (HPLC)at baseline and 4, 12, 24 and 48 weeks during the first 48 weeks of intervention.Four participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Best-spectacle Corrected Visual Acuity (BSCVA) During the Intervention</measure>
    <time_frame>at baseline and 24 weeks, 48 weeks, 2 years during the intervention</time_frame>
    <description>best-spectacle corrected visual acuity (BSCVA) measured by ETDRS chart at baseline and 24 weeks, 48 weeks, 2 years during the intervention. Four participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Contrast Sensitivity (CSF) Measured by CSV-100 During the Intervention</measure>
    <time_frame>at baseline, 24, 48 weeks and 2 years during the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Flash Recovery Time (FRT) Measured by MDD-2 Macular Adaptometer</measure>
    <time_frame>at baseline, 24, 48 weeks and 2 years during the intervention</time_frame>
    <description>Flash recovery time (FRT) was measured by MDD-2 macular adaptometer at baseline, 24, 48 and 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Multifocal Electroretinogram (mfERG) at 48 Weeks</measure>
    <time_frame>at baseline and 48 weeks during the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Microperimetry (MP) During the Intervention</measure>
    <time_frame>at baseline, 24, 48 weeks and 2 years during the intervention</time_frame>
    <description>Microperimetry (MP) was measured by the MP1 Microperimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Food Pattern From Baseline by Food Frequency Questionnaire During the Intervention</measure>
    <time_frame>at baseline, 24, 48 weeks and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>starch in hard shell gelatine capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low lutein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low lutein group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High lutein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high lutein group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low lutein zeaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lutein plus zeaxanthin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High zeaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zeaxanthin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high lutein zeaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zeaxanthin plus lutein group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>low lutein</intervention_name>
    <description>one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
    <arm_group_label>Low lutein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high lutein</intervention_name>
    <description>one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
    <arm_group_label>High lutein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lutein plus zeaxanthin</intervention_name>
    <description>one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
    <arm_group_label>Low lutein zeaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high zeaxanthin</intervention_name>
    <description>one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks</description>
    <arm_group_label>High zeaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zeaxanthin plus lutein</intervention_name>
    <description>one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks</description>
    <arm_group_label>high lutein zeaxanthin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged over 50 years, Chinese of the Han nationality

          -  diagnosed as age-related macular degeneration

          -  did not take lutein or zeaxanthin supplements in the past half a year

          -  good general health

          -  corrected visual acuity above 0.25 (20/80)

          -  did not take optical laser or medical treatments

        Exclusion Criteria:

          -  had other ocular diseases, such as glaucoma, macular pucker, optic neuropathy,
             diabetic retinopathy etc.

          -  had nervous system diseases, stroke, Type I diabetes

          -  had diseases effected nutrients absorption, such as Crohn' s disease

          -  had turbid ocular media or transplanted intraocular lenses

          -  reported abnormal digestive condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoming Lin, M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haidian District</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <results_first_submitted>July 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xiaoming Lin</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lutein</keyword>
  <keyword>zeaxanthin</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>supplementation</keyword>
  <keyword>macular pigment optical density</keyword>
  <keyword>visual function</keyword>
  <keyword>serum concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>We added &quot;High Zeaxanthin&quot; and &quot;High Lutein Zeaxanthin&quot; Arms at the seconde year for additional information on the effect of zeaxanthin on MPOD and visual functions. Therefore, we did not measure the changes of serum concentration, and only measured the change of MOPD and visual functions at baseline and 48 weeks, in the two new groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Lutein</title>
          <description>low lutein group
low lutein: one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>starch in hard shell gelatine capsules
placebo: Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
        </group>
        <group group_id="P3">
          <title>High Lutein</title>
          <description>high lutein group
high lutein: one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
        </group>
        <group group_id="P4">
          <title>Low Lutein Zeaxanthin</title>
          <description>lutein plus zeaxanthin group
lutein plus zeaxanthin: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
        </group>
        <group group_id="P5">
          <title>High Zeaxanthin</title>
          <description>zeaxanthin group
high zeaxanthin: one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks</description>
        </group>
        <group group_id="P6">
          <title>High Lutein Zeaxanthin</title>
          <description>Zeaxanthin plus lutein group
zeaxanthin plus lutein: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>4 participants was excluded during the analysis since they did not finish the intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>Low Lutein</title>
          <description>low lutein group
low lutein: one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>starch in hard shell gelatine capsules
placebo: Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
        </group>
        <group group_id="B3">
          <title>High Lutein</title>
          <description>high lutein group
high lutein: one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
        </group>
        <group group_id="B4">
          <title>Low Lutein Zeaxanthin</title>
          <description>lutein plus zeaxanthin group
lutein plus zeaxanthin: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
        </group>
        <group group_id="B5">
          <title>High Zeaxanthin</title>
          <description>zeaxanthin group
high zeaxanthin: one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks</description>
        </group>
        <group group_id="B6">
          <title>High Lutein Zeaxanthin</title>
          <description>Zeaxanthin plus lutein group
zeaxanthin plus lutein: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="28"/>
            <count group_id="B7" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="8.3"/>
                    <measurement group_id="B2" value="69.0" spread="7.5"/>
                    <measurement group_id="B3" value="69.3" spread="6.9"/>
                    <measurement group_id="B4" value="68.5" spread="6.9"/>
                    <measurement group_id="B5" value="69.7" spread="5.4"/>
                    <measurement group_id="B6" value="69.1" spread="8.1"/>
                    <measurement group_id="B7" value="69.2" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years</title>
        <description>Macular pigment is found in the center of the retina known as the macula and is made up of the carotenoids lutein and zeaxanthin. This pigment serves to protect the macula from harmful blue light. The MPOD ranges from 0 to 1, with higher scores corresponding with greater density (protection). The autofluorescence picture of subject's macular was analyzed for MPOD values.
4 participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
        <time_frame>at baseline and 24 weeks, 48 weeks, 2 years during the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>starch in hard shell gelatine capsules
placebo: Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Low Lutein</title>
            <description>low lutein group
low lutein: one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
          </group>
          <group group_id="O3">
            <title>High Lutein</title>
            <description>high lutein group
high lutein: one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
          </group>
          <group group_id="O4">
            <title>Low Lutein Zeaxanthin</title>
            <description>lutein plus zeaxanthin group
lutein plus zeaxanthin: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
          </group>
          <group group_id="O5">
            <title>High Zeaxanthin</title>
            <description>zeaxanthin group
high zeaxanthin: one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>High Lutein Zeaxanthin</title>
            <description>Zeaxanthin plus lutein group
zeaxanthin plus lutein: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years</title>
          <description>Macular pigment is found in the center of the retina known as the macula and is made up of the carotenoids lutein and zeaxanthin. This pigment serves to protect the macula from harmful blue light. The MPOD ranges from 0 to 1, with higher scores corresponding with greater density (protection). The autofluorescence picture of subject's macular was analyzed for MPOD values.
4 participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
          <units>density units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.315" spread="0.144"/>
                    <measurement group_id="O2" value="0.307" spread="0.142"/>
                    <measurement group_id="O3" value="0.315" spread="0.122"/>
                    <measurement group_id="O4" value="0.320" spread="0.118"/>
                    <measurement group_id="O5" value="0.327" spread="0.117"/>
                    <measurement group_id="O6" value="0.300" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.310" spread="0.102"/>
                    <measurement group_id="O2" value="0.353" spread="0.125"/>
                    <measurement group_id="O3" value="0.395" spread="0.120"/>
                    <measurement group_id="O4" value="0.356" spread="0.150"/>
                    <measurement group_id="O5" value="NA">High zeaxanthin Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of MPOD from baseline to 48 weeks is all we needed for this purpose.</measurement>
                    <measurement group_id="O6" value="NA">&quot;High Lutein Zeaxanthin&quot; Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of MPOD from baseline to 48 weeks is all we needed for this purpose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.316" spread="0.110"/>
                    <measurement group_id="O2" value="0.371" spread="0.188"/>
                    <measurement group_id="O3" value="0.424" spread="0.142"/>
                    <measurement group_id="O4" value="0.384" spread="0.125"/>
                    <measurement group_id="O5" value="0.384" spread="0.139"/>
                    <measurement group_id="O6" value="0.383" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.324" spread="0.163"/>
                    <measurement group_id="O2" value="0.442" spread="0.127"/>
                    <measurement group_id="O3" value="0.441" spread="0.133"/>
                    <measurement group_id="O4" value="0.383" spread="0.149"/>
                    <measurement group_id="O5" value="NA">High zeaxanthin Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of MPOD from baseline to 48 weeks is all we needed for this purpose.</measurement>
                    <measurement group_id="O6" value="NA">&quot;High Lutein Zeaxanthin&quot; Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of MPOD from baseline to 48 weeks is all we needed for this purpose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no group difference</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Serum Xanthophylls Concentrations During the Intervention</title>
        <description>Changes of serum xanthophylls concentrations measured by high performance liquid chromatograph (HPLC)at baseline and 4, 12, 24 and 48 weeks during the first 48 weeks of intervention.Four participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
        <time_frame>at baseline and 4, 12, 24 and 48 weeks during the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>starch in hard shell gelatine capsules
placebo: Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Low Lutein</title>
            <description>low lutein group
low lutein: one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
          </group>
          <group group_id="O3">
            <title>High Lutein</title>
            <description>high lutein group
high lutein: one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
          </group>
          <group group_id="O4">
            <title>Low Lutein Zeaxanthin</title>
            <description>lutein plus zeaxanthin group
lutein plus zeaxanthin: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Serum Xanthophylls Concentrations During the Intervention</title>
          <description>Changes of serum xanthophylls concentrations measured by high performance liquid chromatograph (HPLC)at baseline and 4, 12, 24 and 48 weeks during the first 48 weeks of intervention.Four participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.330" spread="0.404"/>
                    <measurement group_id="O2" value="0.318" spread="0.251"/>
                    <measurement group_id="O3" value="0.301" spread="0.225"/>
                    <measurement group_id="O4" value="0.244" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" spread="0.206"/>
                    <measurement group_id="O2" value="0.870" spread="0.573"/>
                    <measurement group_id="O3" value="1.041" spread="0.661"/>
                    <measurement group_id="O4" value="0.965" spread="0.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.355" spread="0.356"/>
                    <measurement group_id="O2" value="1.058" spread="0.571"/>
                    <measurement group_id="O3" value="1.450" spread="0.930"/>
                    <measurement group_id="O4" value="1.121" spread="0.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.281" spread="0.261"/>
                    <measurement group_id="O2" value="0.973" spread="0.618"/>
                    <measurement group_id="O3" value="1.450" spread="0.856"/>
                    <measurement group_id="O4" value="1.109" spread="0.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.403" spread="0.225"/>
                    <measurement group_id="O2" value="1.350" spread="0.503"/>
                    <measurement group_id="O3" value="1.876" spread="0.907"/>
                    <measurement group_id="O4" value="1.136" spread="0.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no group difference</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Best-spectacle Corrected Visual Acuity (BSCVA) During the Intervention</title>
        <description>best-spectacle corrected visual acuity (BSCVA) measured by ETDRS chart at baseline and 24 weeks, 48 weeks, 2 years during the intervention. Four participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
        <time_frame>at baseline and 24 weeks, 48 weeks, 2 years during the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>starch in hard shell gelatine capsules
placebo: Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Low Lutein</title>
            <description>low lutein group
low lutein: one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
          </group>
          <group group_id="O3">
            <title>High Lutein</title>
            <description>high lutein group
high lutein: one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
          </group>
          <group group_id="O4">
            <title>Low Lutein Zeaxanthin</title>
            <description>lutein plus zeaxanthin group
lutein plus zeaxanthin: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
          </group>
          <group group_id="O5">
            <title>High Zeaxanthin</title>
            <description>zeaxanthin group
high zeaxanthin: one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks</description>
          </group>
          <group group_id="O6">
            <title>High Lutein Zeaxanthin</title>
            <description>Zeaxanthin plus lutein group
zeaxanthin plus lutein: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Best-spectacle Corrected Visual Acuity (BSCVA) During the Intervention</title>
          <description>best-spectacle corrected visual acuity (BSCVA) measured by ETDRS chart at baseline and 24 weeks, 48 weeks, 2 years during the intervention. Four participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.037" spread="9.338"/>
                    <measurement group_id="O2" value="54.769" spread="10.285"/>
                    <measurement group_id="O3" value="54.539" spread="8.056"/>
                    <measurement group_id="O4" value="56.840" spread="6.440"/>
                    <measurement group_id="O5" value="56.481" spread="7.073"/>
                    <measurement group_id="O6" value="55.038" spread="7.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.444" spread="12.509"/>
                    <measurement group_id="O2" value="54.042" spread="10.519"/>
                    <measurement group_id="O3" value="56.444" spread="8.617"/>
                    <measurement group_id="O4" value="56.160" spread="14.907"/>
                    <measurement group_id="O5" value="NA">High zeaxanthin Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of BSCVA from baseline to 48 weeks is all we needed for this purpose.</measurement>
                    <measurement group_id="O6" value="NA">&quot;High Lutein Zeaxanthin&quot; Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of BSCVA from baseline to 48 weeks is all we needed for this purpose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.148" spread="10.741"/>
                    <measurement group_id="O2" value="56.250" spread="10.920"/>
                    <measurement group_id="O3" value="56.846" spread="10.035"/>
                    <measurement group_id="O4" value="60.875" spread="4.919"/>
                    <measurement group_id="O5" value="61.600" spread="8.093"/>
                    <measurement group_id="O6" value="58.500" spread="9.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.115" spread="12.385"/>
                    <measurement group_id="O2" value="56.840" spread="7.587"/>
                    <measurement group_id="O3" value="56.074" spread="7.770"/>
                    <measurement group_id="O4" value="56.600" spread="11.839"/>
                    <measurement group_id="O5" value="NA">High zeaxanthin Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of BSCVA from baseline to 48 weeks is all we needed for this purpose.</measurement>
                    <measurement group_id="O6" value="NA">&quot;High Lutein Zeaxanthin&quot; Arm was added after the first 48 weeks to give additional information on the effect of zeaxanthin on MPOD and visual functions, therefore, the change of BSCVA from baseline to 48 weeks is all we needed for this purpose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is &quot;no group difference&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Contrast Sensitivity (CSF) Measured by CSV-100 During the Intervention</title>
        <time_frame>at baseline, 24, 48 weeks and 2 years during the intervention</time_frame>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Flash Recovery Time (FRT) Measured by MDD-2 Macular Adaptometer</title>
        <description>Flash recovery time (FRT) was measured by MDD-2 macular adaptometer at baseline, 24, 48 and 96 weeks</description>
        <time_frame>at baseline, 24, 48 weeks and 2 years during the intervention</time_frame>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Multifocal Electroretinogram (mfERG) at 48 Weeks</title>
        <time_frame>at baseline and 48 weeks during the intervention</time_frame>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Microperimetry (MP) During the Intervention</title>
        <description>Microperimetry (MP) was measured by the MP1 Microperimeter</description>
        <time_frame>at baseline, 24, 48 weeks and 2 years during the intervention</time_frame>
        <posting_date>12/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Food Pattern From Baseline by Food Frequency Questionnaire During the Intervention</title>
        <time_frame>at baseline, 24, 48 weeks and 2 years</time_frame>
        <posting_date>12/2015</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, and ask for notable adverse effects for an average interval of 1 month.</time_frame>
      <desc>4 participants was excluded during the analysis since they did not finish the intervention. Three did not finish the follow up, while one died from breast cancer. Subjects were encouraged to report any adverse effects immediately, and were asked specifically about adverse events such as carotenoderma every month during visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>starch in hard shell gelatine capsules
placebo: Placebo, one gelatine capsule containing starch per day, for 96 weeks</description>
        </group>
        <group group_id="E2">
          <title>Low Lutein</title>
          <description>low lutein group
low lutein: one gelatine capsule containing 10mg lutein per day, for 96 weeks</description>
        </group>
        <group group_id="E3">
          <title>High Lutein</title>
          <description>high lutein group
high lutein: one gelatine capsule containing 20mg lutein per day, for 96 weeks</description>
        </group>
        <group group_id="E4">
          <title>Low Lutein Zeaxanthin</title>
          <description>lutein plus zeaxanthin group
lutein plus zeaxanthin: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks</description>
        </group>
        <group group_id="E5">
          <title>High Zeaxanthin</title>
          <description>zeaxanthin group
high zeaxanthin: one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks</description>
        </group>
        <group group_id="E6">
          <title>High Lutein Zeaxanthin</title>
          <description>Zeaxanthin plus lutein group
zeaxanthin plus lutein: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Xiaoming Lin</name_or_title>
      <organization>Peking University</organization>
      <phone>010-82805336</phone>
      <email>linbjmu@bjmu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

